ADC Therapeutics SA 6-K, filed Aug 14, 2020

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDERTHE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2020.

Commission File Number: 001-39071

ADC Therapeutics SA

(Exact name of registrant as specifiedin its charter)

Biopôle

Routede la Corniche 3B

1066 Epalinges

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

ADC THERAPEUTICS SA

Dominique Graz has notified the Company of his decision to resign as General Counsel and Secretary of ADC Therapeutics SA to pursue a new opportunity, effective September 30, 2020.

Michael Forer, Vice Chairman & Executive Vice President, will, in addition to his current positions, assume the General Counsel role effective October 1, 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.